PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will present new data on iron dysregulation and ferroptosis role in age related macular degeneration (AMD) during an oral presentation at 25th EURETINA Congress1, the major ophthalmology conference being held in Paris this week 4-7 September.AMD is the leading cause of central vision loss in the elderly, affecting 200 million people worldwide. AMD's pathogenesis is complex, and the disease still represents a high unmet need. Growing evidence identifies iron overload as a key factor in AMD by promoting oxidative stress, inflammation, and ferroptosis, driving progression from dry AMD to geographic atrophy (GA). Transferrin, an endogenous glycoprotein, regulates iron homeostasis by binding and transporting iron in a non-toxic form, preventing harmful accumulation.In collaboration with Inserm and Cochin Hospital (Paris), PulseSight explored iron-transferrin imbalance in one of the largest aqueous humor datasets to date from dry AMD/GA patients and age-matched controls patients. The study confirmed elevated iron and increased transferrin saturation in aqueous humors of AMD patients, providing clinical confirmation of iron dysregulation in the disease and reinforcing the therapeutic relevance of iron modulation in GA — still an underexplored treatment avenue.Dr. Bordet ...Full story available on Benzinga.com